Moehs Group, a leading international group in the production of active pharmaceutical ingredients, has signed an exclusive agreement with EUROAPI to take over the production of Metamizole, the active ingredient of Nolotil, at its facilities in Spain. This exclusive agreement between Moehs Group and EUROAPI aims to complete the evaluation of the technical transfer of the Metamizole Magnesium and Metamizole Sodium API production from the EUROAPI Frankfurt site to a Moehs facility in Spain.

In a context where many pharmaceutical companies opt to offshore their production, Moehs reaffirms its commitment to local manufacturing in Europe, stressing the importance of ensuring a secure and robust supply chain, especially for key markets such as Spain and Germany. The decision also responds to the growing need to prepare the European pharmaceutical sector for potential health crises, as was the case with the COVID-19 pandemic.

Javier del Río, CEO of Moehs, underlined the relevance of this agreement:

‘We are excited to collaborate with EUROAPI in the production of Metamizole in Spain, contributing to the manufacture and supply of medicines for European citizens with active ingredients produced in Europe. With this agreement we reinforce our position in maintaining production in Europe to ensure supplies in accordance with the Medicines for Europe guidelines.